• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.
    公开号:US20010008632A1
    申请号:US09/331,023
    申请日:1997-12-16
    公开日:2001-07-19
    发明作者:Bernhard Freund；Bernd Zierenberg
    申请人:Boehringer Ingelheim Pharma GmbH and Co KG；
    IPC主号:A61K9-0078
    专利说明:
    [0001] The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols for inhalation. [0001]
    [0002] In the last 20 years, the use of dosage aerosols has become a strong part of the therapy of obstructive lung diseases, especially asthma. Usually, fluorochlorohydrocarbons are used as propellant gases. Following the recognition of the ozone damaging potential of these propellant gases, attempts to develop alternatives have increased. One alternative is the development of nebulisers, where aqueous solutions of pharmacologically active substance are sprayed under high pressure so that a mist of inhalable particles results. The advantage of these nebulisers is that they completely dispense with the use of propellant gases. [0002]
    [0003] Such nebulisers are, for example, described in PCT Patent Application WO91/14468, herein incorporated by reference. With the nebulisers described here, active ingredients solutions in defined volumes are sprayed through small jets under high pressure, so that inhalable aerosols with a mean particle size of between 3 and 10 micrometers result. A further developed embodiment of the aforementioned nebuliser is described in PCT/EP96/-04351. The nebuliser portrayed in FIG. 6 carries the trade mark Respimat®. [0003]
    [0004] Usually, pharmaceuticals intended for inhalation are dissolved in an aqueous or ethanolic solution, and according to the solution characteristics of the active substances, solvent mixtures of water and ethanol may also be suitable. [0004]
    [0005] Other components of the solvent are, apart from water and/or ethanol, optionally other cosolvents, and also the pharmaceutical preparation may also additionally contain flavourings and other pharmacological additives. Examples of cosolvents are those which contain hydroxyl groups or other polar groups, for example alcohols—especially isopropylalcohol, glycols—especially propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. Cosolvents are suitable for increasing the solubility of adjuvant materials and, if necessary, active ingredients. [0005]
    [0006] The proportion of dissolved pharmaceutical in the finished pharmaceutical preparation is between 0.001 and 30%—preferably between 0.05 and 3%, especially 0.01 to 2% (weight/volume). The maximum concentration of pharmaceutical is dependent on the solubility in solvent and on the dosage required to achieve the desired therapeutical effect. [0006]
    [0007] All substances which are suitable for application by inhalation and which are soluble in the specified solvent can be used as pharmaceuticals in the new preparations. Pharmaceuticals for the treatment of diseases of the respiratory passages are of especial interest. Therefore, of especial interest are betamimetics, anticholinergics, antiallergics, antihistamines and steroids, as well as combinations of these active ingredients. [0007]
    [0008] It was found, in a series of examinations, that the nebuliser described above can feature spraying anomalies when using aqueous pharmaceutical solutions (generally, double distilled or demineralised (ion exchanged) water is used as a solvent). These spraying anomalies represent an alteration of the spraying pattern of the aerosol, with the consequence that in extreme cases an exact dose can no longer be guaranteed to the patient as a result of the altered mean droplet size distribution (alteration to the lung accessible part of the aerosol). These spraying anomalies especially occur when the nebuliser is used at intervals, for example with breaks of approximately 3 or more days between utilisation. It is possible that these spraying anomalies, which in extreme cases can lead to a dysfunction of the nebuliser, are as a result of microscopic deposits in the area of the jet opening. [0008]
    [0009] Surprisingly, it was discovered that these spraying anomalies no longer occur when the aqueous pharmaceutical preparations which are to be sprayed contain a defined effective quantity of a complexing agent, especially of EDTA (ethylenediamine tetraacetic acid) or salts thereof. The aqueous pharmaceutical preparations according to the invention contain water as a solvent, but if necessary ethanol can be added to increase the solubility up to 70% (by volume), preferably between 30 and 60% (by volume). [0009]
    [0010] Other pharmacological adjuvants such as preservatives, especially benzalkonium chloride, can be added. The preferred quantity of preservative, especially benzalkonium chloride, is between 8 and 12 mg/100 ml solution. [0010]
    [0011] Suitable complexing agents are those which are pharmacologically acceptable, especially those which are already approved by medical regulating authorities. EDTA, nitrilotriacetic acid, citric acid and ascorbic acid and their salts are especially suitable. The disodium salt of ethylenediaminetetraacetic acid is especially preferred. [0011]
    [0012] The quantity of complexing agent is selected so that an effective quantity of complexing agent is added to prevent further occurrence of spraying anomalies. [0012]
    [0013] The effective quantity of the complexing agent Na-EDTA is between 10 and 1000 mg/100 ml solution, especially between 10 and 100 mg/100 ml solution. The preferred range of the quantity of complexing agent is between 25 and 75 mg/100 ml solution, especially between 25 and 50 mg/100 ml solution. [0013]
    [0014] The following named compounds can principally be used as active ingredients, singly or in combination, in the aqueous pharmaceutical preparation according to the invention. In individual cases, it may be required to add a higher quantity of ethanol or a solution mediator to improve solubility. [0014]
    [0015] Tiotropium bromide, 3-[(hydroxydi-2-thienylacetyl)oxy] -8,8-dimethyl-8-azoniabicyclo[3.2.1]oct-6-ene-bromide [0015] As betamimetics:Bambuterol Bitolterol Carbuterol Formoterol Clenbuterol Fenoterol Hexoprenaline Procaterol Ibuterol Pirbuterol Salmeterol Tulobuterol Reproterol Salbutamol Sulfonterol Terbutaline
    [0016] 1-(2-Fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, [0016]
    [0017] erythro-5′-hydroxy-8′-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one, [0017]
    [0018] 1-(4-Amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butyl-amino)ethanol, [0018]
    [0019] 1-(4-Ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol. [0019]
    [0020] As anticholinergics: [0020]
    [0021] Ipratropium bromide [0021]
    [0022] Oxitropium bromide [0022]
    [0023] Trospium chloride [0023]
    [0024] N-β-fluoroethylene nortropine benzylate methobromide [0024]
    [0025] As steroids: [0025]
    [0026] Budesonide [0026]
    [0027] Beclometasone (or the 17,21-dipropionate) [0027]
    [0028] Dexamethasone-21-isonicotinate [0028]
    [0029] Flunisolide [0029]
    [0030] As antiallergics: [0030]
    [0031] Disodium cromoglycate [0031]
    [0032] Nedocromil [0032]
    [0033] Epinastine [0033]
    [0034] Examples of steroids which can be used as active ingredients in the pharmaceutical preparations according to the invention: [0034] Seratrodast Mycophenolate mofetil Pranlukast Zileutone Butixocort Budesonide Deflazacort Fluticasone Promedrol Mometasone furoate Tipredane Beclomethasone, Douglas Icomethasone enbutate Ciclometasone Cloprednol Fluocortin butyl Halometasone Deflazacort Alclometasone Ciclometasone Alisactide Prednicarbate Hydrocortisone-butyrate propionate Tixocortol-pivalate Alclometasane-dipropionate Lotrisone Canesten-HC Deprodone Fluticasone-propionate Methylprednisolone- Halopredone-acetate Aceponate Mometasone Mometasone-furoate Hydrocortisone-aceponate Mometasone Ulobetasol-propionate Aminoglutethimide Triamcinolone Hydrocortisone Meprednisone Fluorometholone Dexamethasone Betamethasone Medrysone Fluclorolone acetonide Fluocinolone acetonide Paramethasone-acetate Deprodone Propionate Aristocort-diacetate Fluocinonide Mazipredone Difluprednate Betamethasone valerate Dexamethasone isonicotinate Beclomethasone-Dipropionate Fluocortolone capronate Formocortal Triamcinolone-Hexacetonide Cloprednol Formebolone Clobetasone Endrisone Flunisolide Halcinonide Fluazacort Clobetasol Hydrocortisone-17-Butyrate Diflorasone Fluocortin Amcinonide Betamethasone Dipropionate Cortivazol Betamethasone adamantoate Fluodexane Trilostane Budesonide Clobetasone Demetex Trimacinolon Benetonide9-α-chloro-6-α-fluoro-11-β-17-α-dihydroxy-16-α-methyl-3- oxo-1,4-androstadiene-17-β-carboxylic acid-methylester-17- propionate.
    [0035] Other especially suitable active ingredients for the production of aqueous pharmaceutical preparations for applications by inhalation are: [0035]
    [0036] β-Sympatico-mimetics; [0036]
    [0037] e.g. Fenoterol, Salbutamol, Formoterol, Terbutalin; [0037]
    [0038] Anticholinergics; [0038]
    [0039] e.g. Ipatropium, Oxitropium, Thiotropium; [0039]
    [0040] Steroids; [0040]
    [0041] e.g. Beclomethasone dipropionate, Budesonide, Flunisolide; [0041]
    [0042] Peptides; [0042]
    [0043] e.g. insulin; [0043]
    [0044] Pain killers; [0044]
    [0045] e.g. Fentanyl. [0045]
    [0046] It is obvious that those pharmacologically acceptable salts will be used which dissolve in the solvent according to the invention if necessary. [0046]
    [0047] In the following text, the advantage of the pharmaceutical preparation according to the invention will be explained more clearly with Examples. [0047]
    [0048] As a pharmaceutical solution, Ipratropium bromide solution (c=333 mg/100 ml) with a pH value of 3.4, and the preservative benzalkonium chloride (c=10 mg/100 ml) was used. The tested solutions either contained no EDTA or EDTA in a concentration of c=0.1 mg, 1 mg, 50 mg and 75 mg/100 ml as a disodium salt. [0048]
    [0049] Unused Respimat® nebulisers were used for the test (technical data: volumes of the applied pharmaceutical preparation approximately 15 μl, pressure approximately 300 bar, 2 streams impacting from two jet openings of size 5×8 μm). The operation mode for the test is set so that the units are used 5 times, are left to stand for 3 days, and then are used again 5 times, this pattern being repeated. 15 units were examined in each series of measurements, the results with regard to spray anomalies own in Table 1. [0049] TABLE 1 Number of Concentration of nebulisers EDTA in with spray Duration of Test No. mg/100 ml anomalies test in days1 0 mg/100 ml 2 20 2 0 mg/100 ml 5 9 3 0.1 mg/100 ml 5 6 4 1 mg/100 ml 6 6 5 50 mg/100 ml 0 200 6 50 mg/100 ml 0 200 7 75 mg/100 ml 0 200 8 75 mg/100 ml 0 200
    [0050] Formulation Examples (for Fenoterol and Ipatropium bromide) [0050] Composition Components in mg/100 ml Fenoterol 833.3 mg  Benzalkonium chloride 10.0 mg EDTA* 50.0 mg HCl (1n) ad pH 3.2 Ipatropium bromide 333.3 mg  Benzalkonium chloride 10.0 mg EDTA* 50.0 mg HCl (1n) ad pH 3.4
    [0051] In analogy to the above Examples, the following solutions were produced. [0051] Concentration Benzalkonium Active ingredient mg/100 ml chloride EDTA* Solvent Berotec 104-1.667 10 mg 50 mg Water Atrovent  83-1.333 10 mg 50 mg Water Berodual (Atrovent) 41-667  10 mg 50 mg Water (Berotec) 104-1.667 10 mg 50 mg Water Salbutamol 104-1.667 10 mg 50 mg Water Combivent (Atrovent) 167-667   10 mg 50 mg Water (Salbutamol) 833-1.667 10 mg 50 mg Water Ba 679 Br  4-667 10 mg 50 mg Water (Tiotropium- bromide) BEA 2108 Br 17-833  10 mg 50 mg Water Oxivent 416-1.667 10 mg 50 mg Water
    [0052] A concentration range from 10 mg to 20,000 mg/100 ml is conceivable for the active ingredients, depending on the dose per operation and their solubility. The specified doses are calculated based on a therapeutically effective single dose of approximately 12 microliters per operation. The active ingredient concentrations of the pharmaceutical preparations can alter when the volume of the individual dose is altered. [0052]
    [0053] The concentration range for the complexing agents (for example DiNa-EDTA) is between 10 and 1000 mg/100 ml (dependent on the pH value of the solution). The preferred range is between 25 mg and 100 mg/100 ml. [0053]
    [0054] The quantity of benzalkonium chloride should be in the range of 8 to 12 mg/100 ml. [0054]
    [0055] The solutions are set to a pH of 3.2 to 3.4 with 0.1 or 1N HCl. All concentrations relate to 100 ml of finished active ingredient solution. [0055]
    权利要求:
    Claims (21)
    [1" id="US-20010008632-A1-CLM-00001] 1. An aqueous pharmaceutical preparation in the form of a solution for the production of propellant-free aerosols for inhalation comprising a pharmacologically active ingredient, characterised in that the pharmaceutical preparation contains a complexing agent.
    [2" id="US-20010008632-A1-CLM-00002] 2. A pharmaceutical preparation according to
    claim 1 , characterised in that the active ingredient is intended for application by inhalation, especially for the treatment of respiratory passage diseases.
    [3" id="US-20010008632-A1-CLM-00003] 3. A pharmaceutical preparation according to
    claim 2 , characterised in that the active ingredient is selected from the group betamimetics, anticholinergics, antiallergics and/or antihistamines.
    [4" id="US-20010008632-A1-CLM-00004] 4. A pharmaceutical preparation according to claims 1, 2 or 3, characterised in that the active ingredient is selected from the group
    Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual, Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.
    [5" id="US-20010008632-A1-CLM-00005] 5. A pharmaceutical preparation according to any one of
    claims 1 to
    4 , characterised in that the complexing agent is nitrilotriacetic acid, citric acid, ascorbic acid or salts thereof.
    [6" id="US-20010008632-A1-CLM-00006] 6. A pharmaceutical preparation according to any one of
    claims 1 to
    4 , characterised in that the complexing agent is EDTA or a salt thereof.
    [7" id="US-20010008632-A1-CLM-00007] 7. A pharmaceutical preparation according to any one of
    claims 1 to
    6 , characterised in that the concentration of the complexing agent is between 10 and 100 mg/100 ml solution.
    [8" id="US-20010008632-A1-CLM-00008] 8. A pharmaceutical preparation according to
    claim 7 characterised in that the concentration of the complex former is between 25 and 75 mg/100 ml solution.
    [9" id="US-20010008632-A1-CLM-00009] 9. A pharmaceutical preparation according to one of
    claims 1 to
    8 , characterised in that the adjuvant is a preservative.
    [10" id="US-20010008632-A1-CLM-00010] 10. A pharmaceutical preparation according to
    claim 9 , characterised in that the preservative is Benzalkonium chloride.
    [11" id="US-20010008632-A1-CLM-00011] 11. A pharmaceutical preparation according to any one of the previous claims, characterised in that the pharmaceutical preparation contains up to 70% (by volume) ethanol.
    [12" id="US-20010008632-A1-CLM-00012] 12. A pharmaceutical preparation according to one of the previous claims, characterised in that it contains the active ingredient in a concentration of 0.001 to 2 g/100 ml solution.
    [13" id="US-20010008632-A1-CLM-00013] 13. A pharmaceutical preparation according to any one of the previous claims, characterised in that it contains pharmacologically acceptable adjuvant and flavouring substances.
    [14" id="US-20010008632-A1-CLM-00014] 14. The use of aqueous pharmaceutical preparations in the production of propellant-free aerosols for inhalation, characterised in that the pharmaceutical preparations contain a complexing agent.
    [15" id="US-20010008632-A1-CLM-00015] 15. The use according to
    claim 14 , characterised in that the active ingredient is selected from the group Betamimetics, Anticholinergics, Antiallergics and/or antihistamines.
    [16" id="US-20010008632-A1-CLM-00016] 16. The use according to
    claim 14 or
    15 , characterised in that the active ingredient is selected from the group Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual, Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.
    [17" id="US-20010008632-A1-CLM-00017] 17. The use according to any one of
    claims 14 to
    16 , characterised in that the complexing agent is nitriloacetic acid, citric acid, ascorbic acid or a salt thereof.
    [18" id="US-20010008632-A1-CLM-00018] 18. The use according to any one of
    claims 14 to
    16 , characterised in that the complexing agent is EDTA or a salt thereof.
    [19" id="US-20010008632-A1-CLM-00019] 19. The use according to
    claim 18 , characterised in that the concentration of the complexing agent is between 25 and 75 mg.
    [20" id="US-20010008632-A1-CLM-00020] 20. The use according to any one of
    claims 14 to
    19 , characterised in that the pharmaceutical preparation contains up to 70% (by volume) ethanol.
    [21" id="US-20010008632-A1-CLM-00021] 21. The use according to any one of
    claims 14 to
    20 , characterised in that the pharmaceutical preparation contains active ingredient in a concentration of 0.001 to 2 g/100 ml solution.
    类似技术:
    公开号 | 公开日 | 专利标题
    US7470422B2|2008-12-30|Method for the production of propellant gas-free aerosols from aqueous medicament preparations
    AU740543B2|2001-11-08|New aqueous medicament preparations for the production of propellent gas-free aerosols
    US6491897B1|2002-12-10|Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
    CZ222599A3|2000-02-16|Pharmaceutical preparation
    MXPA99005660A|2000-01-01|New aqueous medicament preparations for the production of propellent gas-free aerosols
    AU3257000A|2000-07-06|New, stable medicinal compositions for generating propellant-free aerosols
    同族专利:
    公开号 | 公开日
    SK81499A3|2000-01-18|
    NO320652B1|2006-01-09|
    AU5663698A|1998-07-17|
    PL189511B1|2005-08-31|
    BG103482A|2000-01-31|
    BRPI9713596C1|2021-05-25|
    HU228494B1|2013-03-28|
    BG64433B1|2005-02-28|
    US20090185983A1|2009-07-23|
    RU2219906C2|2003-12-27|
    JP4659160B2|2011-03-30|
    EG23981A|2008-02-27|
    EP1230916A3|2003-02-05|
    UA64736C2|2004-03-15|
    AT235887T|2003-04-15|
    SK282910B6|2003-01-09|
    SA858B1|2006-04-28|
    KR100496723B1|2005-06-22|
    EE9900307A|2000-02-15|
    CO4920211A1|2000-05-29|
    PT946146E|2003-08-29|
    PL334185A1|2000-02-14|
    HU227012B1|2010-04-28|
    DK0946146T3|2003-04-22|
    PE32899A1|1999-04-23|
    CA2275392C|2004-06-29|
    MY124547A|2006-06-30|
    UY24813A1|2000-09-29|
    RS49803B|2008-06-05|
    AU740543B2|2001-11-08|
    CA2275392A1|1998-07-02|
    EP0946146A2|1999-10-06|
    TW438605B|2001-06-07|
    ES2196388T3|2003-12-16|
    HK1022846A1|2000-08-25|
    ZA9711370B|1998-06-22|
    HU0000520A2|2000-09-28|
    KR20000057683A|2000-09-25|
    NO993004L|1999-06-18|
    YU28499A|2001-09-28|
    HU0600044D0|2006-03-28|
    CN1240347A|2000-01-05|
    TR199901408T2|1999-08-23|
    BR9713596A|2000-04-04|
    ID22481A|1999-10-21|
    DE59709722D1|2003-05-08|
    BR9713596B8|2013-02-19|
    NO993004D0|1999-06-18|
    SI0946146T1|2003-10-31|
    DE19653969A1|1998-06-25|
    US20090099225A1|2009-04-16|
    NZ336825A|2001-09-28|
    WO1998027959A3|1998-08-13|
    EE03949B1|2003-02-17|
    AR008721A1|2000-02-09|
    CN1097455C|2003-01-01|
    BR9713596B1|2013-01-08|
    IL130464A|2004-12-15|
    IL130464D0|2000-06-01|
    EP1230916A2|2002-08-14|
    EP0946146B1|2003-04-02|
    HRP970694B1|2005-06-30|
    WO1998027959A2|1998-07-02|
    HRP970694A2|1998-10-31|
    HU0000520A3|2000-10-30|
    JP2001507343A|2001-06-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20030181478A1|2000-10-31|2003-09-25|Boehringer Ingelheim Pharma Kg|Inhalable formulation of a solution containing a tiotropium salt|
    US20030216413A1|2000-09-29|2003-11-20|Root-Bernstein Robert S.|Catecholamine pharmaceutical compositions and methods|
    US20040002548A1|1999-05-12|2004-01-01|Boehringer Ingelheim Pharma Kg|Medicament compositions containing anticholinergically-effective compounds and betamimetics|
    US20040019073A1|2002-04-11|2004-01-29|Boehringer Ingelheim Pharma Gmbh Co. Kg|Aerosol formulation for inhalation containing a tiotropium salt|
    US20040039011A1|2001-03-13|2004-02-26|Boehringer Ingelheim Pharma Kg|Compounds for treating inflammatory diseases|
    US20040048886A1|2002-07-09|2004-03-11|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Pharmaceutical compositions based on new anticholinergics and NK1 receptor antagonists|
    US20040058950A1|2002-07-09|2004-03-25|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors|
    US20040204392A1|2001-04-09|2004-10-14|Christopher Wood|Intermittent lowering of levels of cortisol and other adrenalhormones as treatment of clinical conditions associated with abnormal concentrations of such hormones in man and animals|
    US20040209852A1|2003-04-16|2004-10-21|Imtiaz Chaudry|Formulations and methods for treating rhinosinusitis|
    US20040208830A1|2003-04-16|2004-10-21|Imtiaz Chaudry|Nasal pharmaceutical formulations and methods of using the same|
    US20040248924A1|2001-09-18|2004-12-09|Moesgaard Hanne Anette|Compositions for treatment of common cold|
    US20040265238A1|2003-06-27|2004-12-30|Imtiaz Chaudry|Inhalable formulations for treating pulmonary hypertension and methods of using same|
    US20050025718A1|2003-07-31|2005-02-03|Boehringer Ingelheim International Gmbh|Medicaments for inhalation comprising an anticholinergic and a betamimetic|
    US20050042176A1|2003-07-28|2005-02-24|Boehringer Ingelheim International Gmbh|Medicaments for inhalation comprising a novel anticholinergic and a steroid|
    US20050059643A1|2003-08-05|2005-03-17|Boehringer Ingelheim International Gmbh|Medicaments for inhalation comprising a steroid and a betamimetic|
    US20050107417A1|2003-07-28|2005-05-19|Boehringer Ingelheim International Gmbh|Medicaments for inhalation comprising a novel anticholinergic and a betamimetic|
    US20050194472A1|2004-01-08|2005-09-08|Boehringer Ingelheim International Gmbh|Device for clamping a fluidic component|
    US20050203088A1|2004-01-09|2005-09-15|Boehringer Ingelheim International Gmbh|Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors|
    US20050207983A1|2004-03-05|2005-09-22|Pulmatrix, Inc.|Formulations decreasing particle exhalation|
    US20050222144A1|2002-11-15|2005-10-06|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Medicaments for the treatment of chronic obstructive pulmonary disease|
    US20050220720A1|2002-05-02|2005-10-06|David Edwards|Formulations limiting spread of pulmonary infections|
    US20050255050A1|2004-05-14|2005-11-17|Boehringer Ingelheim International Gmbh|Powder formulations for inhalation, comprising enantiomerically pure beta agonists|
    US20050256115A1|2004-05-14|2005-11-17|Boehringer Ingelheim International Gmbh|Aerosol formulation for the inhalation of beta-agonists|
    US20050272726A1|2004-04-22|2005-12-08|Boehringer Ingelheim International Gmbh|Novel medicaments for the treatment of respiratory diseases|
    US20050288274A1|1999-11-12|2005-12-29|Boehringer Ingelheim Pharma Gmbh|Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane|
    WO2005123064A1|2004-06-10|2005-12-29|Board Of Trustees Of Michigan State University|Adrenergic complement inhaler comprising compounds such as ascorbates tocopherols or polycaboxylic acid chelators|
    US20070041912A1|2003-03-19|2007-02-22|Advanced Inhalation Research, Inc.|Trospium containing compositions|
    US20070053844A1|2005-05-18|2007-03-08|Pulmatrix Inc.|Formulations for alteration of biophysical properties of mucosal lining|
    US20070088160A1|2005-08-15|2007-04-19|Thomas Krueger|Process for the manufacturing of betamimetics|
    US20070142341A1|2003-04-16|2007-06-21|Lester John W|Use of steroid derivatives for the treatment of angiotensin ll related disease e.g. cardiovascular and proliferative disorders|
    US20080038207A1|2005-01-10|2008-02-14|Pulmatrix, Inc.|Method and device for decreasing contamination|
    US20080041369A1|2006-08-18|2008-02-21|Kirsten Radau|Aerosol formulation for the inhalation of beta agonists|
    US20080041370A1|2006-08-18|2008-02-21|Kirsten Radau|Aerosol formulation for the inhalation of beta agonists|
    US20080053430A1|2006-08-22|2008-03-06|Michael Nowak|Aerosol formulation for the inhalation of beta agonists|
    US20080280897A1|2005-11-09|2008-11-13|Michael Aven|Aerosol Formulation for Inhalation|
    US7491719B2|2004-05-14|2009-02-17|Boehringer Ingelheim International Gmbh|Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments|
    US20090076580A1|2007-09-13|2009-03-19|Medtronic, Inc.|Medical electrical lead|
    US20090202447A1|2006-05-20|2009-08-13|Christoph Kreher|Inhalant aerosol formulations containing ethanol|
    US20100056559A1|2006-05-19|2010-03-04|Boehringer Ingelheim International Gmbh|Propellant-free aerosol formulation for inhalation|
    US20100144784A1|2006-05-19|2010-06-10|Boehringer Ingelheim International Gmbh|Aerosol formulation|
    US20100197719A1|1999-05-12|2010-08-05|Boehringer Ingelheim Pharma Kg|Medicament compositions containing anticholinergically-effective compounds and betamimetics|
    US8394791B2|2008-02-22|2013-03-12|Boehringer Ingelheim International Gmbh|Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug|
    US8858917B2|2002-05-02|2014-10-14|President And Fellows Of Harvard College|Methods for limiting spread of pulmonary infections|
    US8992983B2|2010-08-30|2015-03-31|Pulmatrix, Inc.|Respirably dry powder comprising calcium lactate, sodium chloride and leucine|
    US9061352B2|2010-08-30|2015-06-23|Pulmatrix, Inc.|Dry powder formulations and methods for treating pulmonary diseases|
    US9433576B2|2010-09-29|2016-09-06|Pulmatrix, Inc.|Cationic dry powders|
    US9545487B2|2012-04-13|2017-01-17|Boehringer Ingelheim International Gmbh|Dispenser with encoding means|
    US9642798B2|2010-09-29|2017-05-09|Pulmatrix, Inc.|Monovalent metal cation dry powders for inhalation|
    US9682202B2|2009-05-18|2017-06-20|Boehringer Ingelheim International Gmbh|Adapter, inhalation device, and atomizer|
    US9724482B2|2009-11-25|2017-08-08|Boehringer Ingelheim International Gmbh|Nebulizer|
    US9737518B2|2013-04-01|2017-08-22|Pulmatrix Operating Company, Inc.|Tiotropium dry powders|
    US9744313B2|2013-08-09|2017-08-29|Boehringer Ingelheim International Gmbh|Nebulizer|
    US9757750B2|2011-04-01|2017-09-12|Boehringer Ingelheim International Gmbh|Medicinal device with container|
    US9827384B2|2011-05-23|2017-11-28|Boehringer Ingelheim International Gmbh|Nebulizer|
    US9943654B2|2010-06-24|2018-04-17|Boehringer Ingelheim International Gmbh|Nebulizer|
    US10004857B2|2013-08-09|2018-06-26|Boehringer Ingelheim International Gmbh|Nebulizer|
    US10011906B2|2009-03-31|2018-07-03|Beohringer Ingelheim International Gmbh|Method for coating a surface of a component|
    US10016568B2|2009-11-25|2018-07-10|Boehringer Ingelheim International Gmbh|Nebulizer|
    US10099022B2|2014-05-07|2018-10-16|Boehringer Ingelheim International Gmbh|Nebulizer|
    US10124125B2|2009-11-25|2018-11-13|Boehringer Ingelheim International Gmbh|Nebulizer|
    US10124129B2|2008-01-02|2018-11-13|Boehringer Ingelheim International Gmbh|Dispensing device, storage device and method for dispensing a formulation|
    US10195374B2|2014-05-07|2019-02-05|Boehringer Ingelheim International Gmbh|Container, nebulizer and use|
    US10589039B2|2012-02-29|2020-03-17|Pulmatric Operating Company, Inc.|Methods for producing respirable dry powders|
    US10722666B2|2014-05-07|2020-07-28|Boehringer Ingelheim International Gmbh|Nebulizer with axially movable and lockable container and indicator|MX3864E|1975-05-27|1981-08-26|Syntex Corp|A PROCESS TO PREPARE THE CRYSTALLINE COMPOUND 6-FLUIRO-11B 21-DIHIROXI-16 17-ISOPROPILIDENDIOXIPREGNA-1 4-DIEN-3 20-DIONA|
    DE3431727A1|1984-08-29|1986-03-13|Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen|Nasal spray for coryza and influenza with a content of zinc gluconate|
    JPH0645538B2|1987-09-30|1994-06-15|日本化薬株式会社|Nitroglycerin spray|
    GB8825892D0|1988-11-04|1988-12-07|Fisons Plc|Pharmaceutical composition|
    SG45171A1|1990-03-21|1998-01-16|Boehringer Ingelheim Int|Atomising devices and methods|
    EP0754450A1|1990-10-16|1997-01-22|Mayor Pharmaceuticals Laboratories,Inc.|Vitamin-mineral treatment methods and compositions|
    HU221163B1|1992-12-09|2002-08-28|Boehringer Ingelheim Pharma|Stabilized medicinal aerosol solution formulations and process for producing them|
    TW431888B|1994-02-03|2001-05-01|Schering Plough Healthcare|Nasal spray compositions|
    DE726075T1|1995-02-08|1996-12-12|Therapicon Srl|Non-inorganic pharmaceutical saline solutions for endonasal administration|
    WO1997001329A1|1995-06-27|1997-01-16|Boehringer Ingelheim Kg|New, stable medicinal compositions for generating propellant-free aerosols|
    DE19536916A1|1995-10-04|1997-04-10|Boehringer Ingelheim Kg|Inhalative application of 2-amino-6n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole, in particular its - enantiomer, and their pharmacologically acceptable acid addition salts|
    DE19536902A1|1995-10-04|1997-04-10|Boehringer Ingelheim Int|Miniature fluid pressure generating device|
    DE19620509A1|1996-05-22|1997-11-27|Hoechst Ag|Use of non-peptide bradykinin antagonist compounds - to treat chronic fibrogenetic liver disease, and acute liver disease, and to prevent complications|
    EP0808627A2|1996-05-22|1997-11-26|Hoechst Aktiengesellschaft|Use of non-peptide bradykinin antagonists for treating and preventing chronic fibrogenetic liver diseases, acute liver diseases and complications thereof|
    US5976573A|1996-07-03|1999-11-02|Rorer Pharmaceutical Products Inc.|Aqueous-based pharmaceutical composition|
    DE19644646A1|1996-10-26|1998-04-30|Mann & Hummel Filter|Filters, in particular for filtering the lubricating oil of an internal combustion engine|
    US20030215396A1|1999-09-15|2003-11-20|Boehringer Ingelheim Pharma Kg|Method for the production of propellant gas-free aerosols from aqueous medicament preparations|
    US20060239930A1|1997-08-04|2006-10-26|Herbert Lamche|Process for nebulizing aqueous compositions containing highly concentrated insulin|
    DE19847969A1|1998-10-17|2000-04-20|Boehringer Ingelheim Pharma|Stable liquid formulation of formoterol in solution or suspension medium, used after dilution for treatment of asthma by inhalation|
    DE19921693A1|1999-05-12|2000-11-16|Boehringer Ingelheim Pharma|Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects|
    US20020111363A1|2000-10-31|2002-08-15|Karin Drechsel|Inhalable formulation of a solution containing a tiotropium salt|
    US20020137764A1|2000-10-31|2002-09-26|Karin Drechsel|Inhalable formulation of a solution containing a tiotropium salt|
    US20020193392A1|2000-11-13|2002-12-19|Christel Schmelzer|Pharmaceutical compositions based on tiotropium salts of salts of salmeterol|
    US20040019073A1|2002-04-11|2004-01-29|Boehringer Ingelheim Pharma Gmbh Co. Kg|Aerosol formulation for inhalation containing a tiotropium salt|DE19733651A1|1997-08-04|1999-02-18|Boehringer Ingelheim Pharma|Aqueous aerosol preparations containing biologically active marrow molecules and processes for producing corresponding aerosols|
    DE19940713A1|1999-02-23|2001-03-01|Boehringer Ingelheim Int|Diffusion resistant cartridge for storing and dosing liquids, especially for producing drug-containing inhalable aerosols, has three-shell structure with collapsible bag, container and rigid housing|
    DE19808295A1|1998-02-27|1999-11-11|Boehringer Ingelheim Int|Medical fluid container|
    DE19847968A1|1998-10-17|2000-04-20|Boehringer Ingelheim Pharma|Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit.|
    SE9803770D0|1998-11-05|1998-11-05|Astra Ab|Dry powder pharmaceutical formulation|
    DE19921693A1|1999-05-12|2000-11-16|Boehringer Ingelheim Pharma|Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects|
    HU0301377A3|2000-10-31|2005-12-28|Boehringer Ingelheim Pharma|Combination pharmaceutical composition in form of inhalative solution containing a tiotropium salt|
    PT1333819E|2000-10-31|2007-10-29|Boehringer Ingelheim Pharma|Inhalative solution formulation containing a tiotropium salt|
    US20020193392A1|2000-11-13|2002-12-19|Christel Schmelzer|Pharmaceutical compositions based on tiotropium salts of salts of salmeterol|
    DE10062712A1|2000-12-15|2002-06-20|Boehringer Ingelheim Pharma|New drug compositions based on anticholinergics and corticosteroids|
    DE10136555A1|2001-07-27|2003-02-13|Boehringer Ingelheim Int|Method for determining the size distribution of particles in an aerosol, especially particles of a medicament involves mixing of a carrier medium with the medicament to produce an appropriately conditioned aerosol|
    NZ550304A|2001-10-26|2008-05-30|Dey L P|An antimicrobial preservative-free albuterol inhalation solution for the relief of bronchospasm in children with asthma|
    JP2010184937A|2001-10-26|2010-08-26|Dey Lp|Albuterol and ipratropium inhalation solution for relieving symptom of chronic obstructive pulmonary disease, kit, method for preparing one vessel containing the inhalation solution and method for preparing the inhalation solution|
    AU3297402A|2001-10-26|2003-10-30|Dey, L.P.|An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease|
    DE10216036A1|2002-04-11|2003-10-23|Boehringer Ingelheim Pharma|Aerosol formulation for inhalation containing a tiotropium salt|
    RS51396B|2002-08-14|2011-02-28|Boehringer Ingelheim Pharma Gmbh & Co.Kg.|Aerosol formulation for inhalation containing an anticholinergic agent|
    BRPI0418802B1|2004-05-25|2016-06-28|Enel Distribuzione Spa|method and apparatus relay for detecting in a power distribution system the wiring phase at a remote location, apparatus for detecting the phase wiring of an unknown phase voltage and remote meter for remote measurement of utility consumption|
    FR2924344B1|2007-12-04|2010-04-16|Pf Medicament|USE OF MEQUITAZINE IN THE FORM OF RACEMATE OR ENANTIOMERS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES INVOLVING HISTAMIC RECEPTORS H4.|
    WO2012150131A1|2011-05-03|2012-11-08|Chiesi Farmaceutici S.P.A.|Improved suspension formulation of a corticosteroid for administration by inhalation|
    RU2479304C1|2012-05-29|2013-04-20|Шолекс Девелопмент Гмбх,|Stable solution of fenoterol hydrobromide|
    RU2493827C1|2012-10-03|2013-09-27|Шолекс Девелопмент Гмбх|Stable combined solution of fenoterol hydrobromide and ipratropium bromide|
    WO2015065223A1|2013-10-28|2015-05-07|Шолекс Девелопмент Гмбх|Stable solution of fenoterol hydrobromide|
    WO2015065219A1|2013-10-28|2015-05-07|Шолекс Девелопмент Гмбх|Ipratropium bromide solution|
    ES2826562T3|2015-05-18|2021-05-18|Glenmark Specialty Sa|Tiotropium Inhalation Solution by Nebulizer|
    WO2022023515A1|2020-07-31|2022-02-03|Chemo Research , S.L.|Combination therapy for inhalation administration|
    法律状态:
    1999-09-16| AS| Assignment|Owner name: BOEHRINGER INGELHEIM PHARMA KG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FREUND, BERNHARD;ZIERENBERG, BERND;REEL/FRAME:010234/0766;SIGNING DATES FROM 19990809 TO 19990812 |
    2003-07-21| STCB| Information on status: application discontinuation|Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
    优先权:
    申请号 | 申请日 | 专利标题
    DE19653969A|DE19653969A1|1996-12-20|1996-12-20|New aqueous pharmaceutical preparation for the production of propellant-free aerosols|
    DE19653969.2||1996-12-20||US10/417,766| US20030215396A1|1999-09-15|2003-04-17|Method for the production of propellant gas-free aerosols from aqueous medicament preparations|
    US11/506,128| US7470422B2|1996-12-20|2006-08-17|Method for the production of propellant gas-free aerosols from aqueous medicament preparations|
    US12/338,812| US20090099225A1|1996-12-20|2008-12-18|Method for the production of propellant gas-free aerosols from aqueous medicament preparations|
    US12/413,828| US20090185983A1|1996-12-20|2009-03-30|Aqueous medicament preparations for the production of propellant gas-free aerosols|
    [返回顶部]